Summary
61.85 1.19(1.95%)09/27/2024
Precision Drilling Corp (PDS)
Precision Drilling Corp (PDS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.95 | -7.04 | -14.66 | -12.20 | -7.60 | -9.56 | 162.06 | 0.75 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 61.85 | |
| Open | 61.58 | |
| High | 62.02 | |
| Low | 60.73 | |
| Volume | 72,386 | |
| Change | 1.19 | |
| Change % | 1.95 | |
| Avg Volume (20 Days) | 49,828 | |
| Volume/Avg Volume (20 Days) Ratio | 1.45 | |
| 52 Week Range | 49.67 - 79.07 | |
| Price vs 52 Week High | -21.78% | |
| Price vs 52 Week Low | 24.51% | |
| Range | 0.43 | |
| Gap Up/Down | -0.74 | |
Fundamentals | ||
| Market Capitalization (Mln) | 864 | |
| EBIDTA | 539,283,008 | |
| PE Ratio | 5.9575 | |
| PEG Ratio | 0.4000 | |
| WallStreet Target Price | 94.16 | |
| Book Value | 112.9550 | |
| Earnings Per Share | 12.0100 | |
| EPS Estimate Current Quarter | 1.9300 | |
| EPS Estimate Next Quarter | 0.1400 | |
| EPS Estimate Current Year | 6.5600 | |
| EPS Estimate Next Year | 9.6700 | |
| Diluted EPS (TTM) | 12.0100 | |
| Revenues | ||
| Profit Marging | 0.1206 | |
| Operating Marging (TTM) | 0.1230 | |
| Return on asset (TTM) | 0.0524 | |
| Return on equity (TTM) | 0.1546 | |
| Revenue TTM | 1,907,035,008 | |
| Revenue per share TTM | 136.7660 | |
| Quarterly Revenue Growth (YOY) | -0.0550 | |
| Quarterly Earnings Growth (YOY) | -0.5450 | |
| Gross Profit (TTM) | 492,593,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 5.9575 | |
| Forward PE | 11.0132 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.8889 | |
| Revenue Enterprise Value | 0.8849 | |
| EBITDA Enterprise Value | 2.6612 | |
| Shares | ||
| Shares Outstanding | 14,478,600 | |
| Shares Float | 14,003,974 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.02 | |
| Insider (%) | 2.07 | |
| Institutions (%) | 58.28 | |
09/23 23:07 EST - seekingalpha.com
Precision Drilling: Get 20% Free Cash Flow Yield At The Cyclical Bottom
U.S. drilling activity is at a cyclical bottom, but Canada is at multiyear highs. The Canadian exposure and its high-spec rigs allow Precision Drilling to maintain a 20% FCF yield even now. Investors can benefit from Precision Drilling's buybacks while waiting for the turnaround in the U.S.
Precision Drilling: Get 20% Free Cash Flow Yield At The Cyclical Bottom
U.S. drilling activity is at a cyclical bottom, but Canada is at multiyear highs. The Canadian exposure and its high-spec rigs allow Precision Drilling to maintain a 20% FCF yield even now. Investors can benefit from Precision Drilling's buybacks while waiting for the turnaround in the U.S.
09/23 10:39 EST - seekingalpha.com
PDS Biotechnology: Continuing The Holding Pattern
PDS Biotechnology is focusing on an HPV-directed immunotherapy as its main near-term hope, with new data presented at the ESMO Congress. Strengths include promising clinical data and a focused pipeline, while risks involve typical biotech uncertainties and financial sustainability. The bottom-line summary suggests a cautious yet optimistic outlook, emphasizing the importance of upcoming clinical milestones and financial health.
PDS Biotechnology: Continuing The Holding Pattern
PDS Biotechnology is focusing on an HPV-directed immunotherapy as its main near-term hope, with new data presented at the ESMO Congress. Strengths include promising clinical data and a focused pipeline, while risks involve typical biotech uncertainties and financial sustainability. The bottom-line summary suggests a cautious yet optimistic outlook, emphasizing the importance of upcoming clinical milestones and financial health.
09/13 06:00 EST - globenewswire.com
Precision Drilling Announces Renewal of Normal Course Issuer Bid
CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) -- This news release contains "forward-looking information and statements" within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the "Cautionary Statement Regarding Forward-Looking Information and Statements" later in this news release.
Precision Drilling Announces Renewal of Normal Course Issuer Bid
CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) -- This news release contains "forward-looking information and statements" within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the "Cautionary Statement Regarding Forward-Looking Information and Statements" later in this news release.
09/09 08:00 EST - globenewswire.com
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024
PRINCETON, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, will present updated data from the VERSATILE-002 trial evaluating first-line treatment with Versamune® HPV (formerly PDS0101) in combination with KEYTRUDA® (pembrolizumab) in patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) during a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2024 on September 14, 2024, in Barcelona, Spain.
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024
PRINCETON, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, will present updated data from the VERSATILE-002 trial evaluating first-line treatment with Versamune® HPV (formerly PDS0101) in combination with KEYTRUDA® (pembrolizumab) in patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) during a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2024 on September 14, 2024, in Barcelona, Spain.
09/03 08:00 EST - globenewswire.com
PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City.
PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City.
08/28 08:45 EST - zacks.com
5 Stocks With Low Price-to-Sales Ratios to Elevate Your Portfolio
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like BTU, PSMT, HG, PDS and GBX hold promise.
5 Stocks With Low Price-to-Sales Ratios to Elevate Your Portfolio
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like BTU, PSMT, HG, PDS and GBX hold promise.
08/27 10:42 EST - zacks.com
Is Precision Drilling (PDS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Precision Drilling (PDS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
08/27 09:50 EST - zacks.com
Despite Fast-paced Momentum, Precision Drilling (PDS) Is Still a Bargain Stock
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Precision Drilling (PDS) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Despite Fast-paced Momentum, Precision Drilling (PDS) Is Still a Bargain Stock
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Precision Drilling (PDS) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
08/27 09:13 EST - zacks.com
New Strong Buy Stocks for August 27th
LYTS, PDS, STRL, MASI and DEC have been added to the Zacks Rank #1 (Strong Buy) List on August 27, 2024.
New Strong Buy Stocks for August 27th
LYTS, PDS, STRL, MASI and DEC have been added to the Zacks Rank #1 (Strong Buy) List on August 27, 2024.
08/07 08:00 EST - globenewswire.com
PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will report financial results for the second quarter of 2024 and provide a business update on Tuesday, August 13, 2024, before the market opens. The press release will be available in the Investor Relations section of the Company's website at www.pdsbiotech.com.
PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will report financial results for the second quarter of 2024 and provide a business update on Tuesday, August 13, 2024, before the market opens. The press release will be available in the Investor Relations section of the Company's website at www.pdsbiotech.com.
08/01 07:45 EST - globenewswire.com
PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer
Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J.
PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer
Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J.
07/31 18:59 EST - seekingalpha.com
Precision Drilling Corporation (PDS) Q2 2024 Earnings Call Transcript
Precision Drilling Corporation (NYSE:PDS ) Q2 2024 Earnings Conference Call July 31, 2024 1:00 PM ET Company Participants Lavonne Zdunich – Vice President-Investor Relations Kevin Neveu – President and Chief Executive Officer Carey Ford – Chief Financial Officer Conference Call Participants Kurt Hallead – Benchmark Luke Lemoine – Piper Sandler Aaron MacNeil – TD Cowen Waqar Syed – ATB Capital Markets Jamie Kubik – CIBC John Gibson – BMO Capital Markets Operator Good day, and thank you for standing by. Welcome to the Precision Drilling Corporation 2024 Second Quarter Conference Call.
Precision Drilling Corporation (PDS) Q2 2024 Earnings Call Transcript
Precision Drilling Corporation (NYSE:PDS ) Q2 2024 Earnings Conference Call July 31, 2024 1:00 PM ET Company Participants Lavonne Zdunich – Vice President-Investor Relations Kevin Neveu – President and Chief Executive Officer Carey Ford – Chief Financial Officer Conference Call Participants Kurt Hallead – Benchmark Luke Lemoine – Piper Sandler Aaron MacNeil – TD Cowen Waqar Syed – ATB Capital Markets Jamie Kubik – CIBC John Gibson – BMO Capital Markets Operator Good day, and thank you for standing by. Welcome to the Precision Drilling Corporation 2024 Second Quarter Conference Call.
07/31 16:01 EST - globenewswire.com
PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will host a conference call to provide a clinical program update on Thursday, August 1, 2024, at 8:00 a.m. ET.
PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will host a conference call to provide a clinical program update on Thursday, August 1, 2024, at 8:00 a.m. ET.
07/30 18:46 EST - zacks.com
Precision Drilling (PDS) Surpasses Q2 Earnings and Revenue Estimates
Precision Drilling (PDS) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of a loss of $0.62 per share. This compares to earnings of $1.21 per share a year ago.
Precision Drilling (PDS) Surpasses Q2 Earnings and Revenue Estimates
Precision Drilling (PDS) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of a loss of $0.62 per share. This compares to earnings of $1.21 per share a year ago.
07/30 16:30 EST - globenewswire.com
Precision Drilling Announces 2024 Second Quarter Unaudited Financial Results
CALGARY, Alberta, July 30, 2024 (GLOBE NEWSWIRE) -- This news release contains “forward-looking information and statements” within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the “Cautionary Statement Regarding Forward-Looking Information and Statements” later in this news release. This news release contains references to certain Financial Measures and Ratios, including Adjusted EBITDA (earnings before income taxes, loss (gain) on investments and other assets, gain on repurchase of unsecured senior notes, finance charges, foreign exchange, gain on asset disposals and depreciation and amortization), Funds Provided by (Used in) Operations, Net Capital Spending, Working Capital and Total Long-term Financial Liabilities. These terms do not have standardized meanings prescribed under International Financial Reporting Standards ( IFRS ) Accounting Standards and may not be comparable to similar measures used by other companies. See “Financial Measures and Ratios” later in this news release.
Precision Drilling Announces 2024 Second Quarter Unaudited Financial Results
CALGARY, Alberta, July 30, 2024 (GLOBE NEWSWIRE) -- This news release contains “forward-looking information and statements” within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the “Cautionary Statement Regarding Forward-Looking Information and Statements” later in this news release. This news release contains references to certain Financial Measures and Ratios, including Adjusted EBITDA (earnings before income taxes, loss (gain) on investments and other assets, gain on repurchase of unsecured senior notes, finance charges, foreign exchange, gain on asset disposals and depreciation and amortization), Funds Provided by (Used in) Operations, Net Capital Spending, Working Capital and Total Long-term Financial Liabilities. These terms do not have standardized meanings prescribed under International Financial Reporting Standards ( IFRS ) Accounting Standards and may not be comparable to similar measures used by other companies. See “Financial Measures and Ratios” later in this news release.
07/23 11:07 EST - zacks.com
Precision Drilling (PDS) Reports Next Week: Wall Street Expects Earnings Growth
Precision Drilling (PDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precision Drilling (PDS) Reports Next Week: Wall Street Expects Earnings Growth
Precision Drilling (PDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/07 05:38 EST - seekingalpha.com
Precision Drilling: Automation Makes It A Buy
Precision Drilling Corporation is experiencing growth in service rigs, driven by Trans Mountain pipeline expansion and regulatory spending requirements, potentially accelerating demand for the stock. Recent plans to reduce debt levels and distribute 25%-35% of FCF to shareholders could further boost stock demand. The business review highlights drilling as the most relevant activity, with potential synergies from CWC Energy Services acquisition and automation technologies enhancing future drilling activities.
Precision Drilling: Automation Makes It A Buy
Precision Drilling Corporation is experiencing growth in service rigs, driven by Trans Mountain pipeline expansion and regulatory spending requirements, potentially accelerating demand for the stock. Recent plans to reduce debt levels and distribute 25%-35% of FCF to shareholders could further boost stock demand. The business review highlights drilling as the most relevant activity, with potential synergies from CWC Energy Services acquisition and automation technologies enhancing future drilling activities.
07/03 16:00 EST - globenewswire.com
Precision Drilling Corporation 2024 Second Quarter Results Conference Call and Webcast
CALGARY, Alberta, July 03, 2024 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) intends to release its 2024 second quarter results after the market closes on Tuesday, July 30, 2024, and has scheduled a conference call to begin at 11:00 a.m. MT (1:00 p.m. ET) on the next day, Wednesday, July 31, 2024.
Precision Drilling Corporation 2024 Second Quarter Results Conference Call and Webcast
CALGARY, Alberta, July 03, 2024 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) intends to release its 2024 second quarter results after the market closes on Tuesday, July 30, 2024, and has scheduled a conference call to begin at 11:00 a.m. MT (1:00 p.m. ET) on the next day, Wednesday, July 31, 2024.
05/20 06:07 EST - https://www.prnewswire.com
Seed Health to Present New Clinical Data on 'DS-01® Daily Synbiotic' for Both Antibiotic Recovery and IBS at Digestive Disease Week 2024
The company will present the results of two clinical trials that expand the potential health impact of its flagship 24-strain probiotic and prebiotic, DS-01® BOSTON, May 20, 2024 /PRNewswire/ -- Seed Health will present new clinical data on its flagship innovation, DS-01® Daily Synbiotic, a 24-strain probiotic and prebiotic, at the upcoming 2024 Digestive Disease Week® (DDW) meeting. The presentations will highlight the results from two randomized, double-blind, placebo-controlled clinical trials: one assessing the recovery effects of DS-01® on individuals during and following antibiotic usage, and another evaluating DS-01® in patients with irritable bowel syndrome (IBS). The findings underscore Seed's mission to transform breakthrough microbiome science into clinically validated consumer health innovations. "DS-01® was formulated to maximize genomic diversity and set an entirely new standard in probiotics," stated Zain Kassam, M.D., M.P.H, Chief Medical Officer at Seed Health. "Our latest clinical data expands DS-01®'s potential health impact, broadens its clinical use cases, and helps dispel the common perception in the medical community that all probiotics are created equal." Dirk Gevers, Ph.D., Chief Scientific Officer at Seed Health, added, "The findings presented at DDW highlight the rigorous biopharma approach we bring to everyday health. We evaluated digestive well-being by studying biopharmaceutical-type biomarkers, exploring possible mechanisms of action in IBS, and conducting deeper microbiome sequencing than typical probiotic trials following antibiotics." DDW Presentation Highlights These presentations will detail the methodology and results from the two clinical trials which have important implications for the application of microbiome science in consumer health and well-being. Seed's Health clinical data on DS-01® Daily Synbiotic for antibiotic recovery and IBS will be presented in the session "Prebiotics, Probiotics and Synbiotics in Health and Disease" on May 20, 2024, from 12:30 PM to 1:30 PM EDT. About Seed HealthSeed Health is a microbiome science company pioneering innovations in probiotics and living medicines to impact human and planetary health. Founded to realize the potential of the microbiome, our platform enables the translation of breakthrough science across a portfolio targeting health outcomes from infancy to aging. Our consumer innovations are commercialized under Seed®, an award-winning, science-first brand known for clinically validated innovations in probiotics, including DS-01® Daily Synbiotic and PDS-08® Pediatric Daily Synbiotic. Our pipeline encompasses both indication-specific and preventive applications for gastrointestinal and digestive health, women's health, skin, pediatrics, brain health, metabolic function, and healthy aging. Our environmental research is conducted under SeedLabs, which was founded to advance novel bacterial interventions to enhance biodiversity and restore ecosystems impacted by human activity. Media Contact[email protected]
Seed Health to Present New Clinical Data on 'DS-01® Daily Synbiotic' for Both Antibiotic Recovery and IBS at Digestive Disease Week 2024
The company will present the results of two clinical trials that expand the potential health impact of its flagship 24-strain probiotic and prebiotic, DS-01® BOSTON, May 20, 2024 /PRNewswire/ -- Seed Health will present new clinical data on its flagship innovation, DS-01® Daily Synbiotic, a 24-strain probiotic and prebiotic, at the upcoming 2024 Digestive Disease Week® (DDW) meeting. The presentations will highlight the results from two randomized, double-blind, placebo-controlled clinical trials: one assessing the recovery effects of DS-01® on individuals during and following antibiotic usage, and another evaluating DS-01® in patients with irritable bowel syndrome (IBS). The findings underscore Seed's mission to transform breakthrough microbiome science into clinically validated consumer health innovations. "DS-01® was formulated to maximize genomic diversity and set an entirely new standard in probiotics," stated Zain Kassam, M.D., M.P.H, Chief Medical Officer at Seed Health. "Our latest clinical data expands DS-01®'s potential health impact, broadens its clinical use cases, and helps dispel the common perception in the medical community that all probiotics are created equal." Dirk Gevers, Ph.D., Chief Scientific Officer at Seed Health, added, "The findings presented at DDW highlight the rigorous biopharma approach we bring to everyday health. We evaluated digestive well-being by studying biopharmaceutical-type biomarkers, exploring possible mechanisms of action in IBS, and conducting deeper microbiome sequencing than typical probiotic trials following antibiotics." DDW Presentation Highlights These presentations will detail the methodology and results from the two clinical trials which have important implications for the application of microbiome science in consumer health and well-being. Seed's Health clinical data on DS-01® Daily Synbiotic for antibiotic recovery and IBS will be presented in the session "Prebiotics, Probiotics and Synbiotics in Health and Disease" on May 20, 2024, from 12:30 PM to 1:30 PM EDT. About Seed HealthSeed Health is a microbiome science company pioneering innovations in probiotics and living medicines to impact human and planetary health. Founded to realize the potential of the microbiome, our platform enables the translation of breakthrough science across a portfolio targeting health outcomes from infancy to aging. Our consumer innovations are commercialized under Seed®, an award-winning, science-first brand known for clinically validated innovations in probiotics, including DS-01® Daily Synbiotic and PDS-08® Pediatric Daily Synbiotic. Our pipeline encompasses both indication-specific and preventive applications for gastrointestinal and digestive health, women's health, skin, pediatrics, brain health, metabolic function, and healthy aging. Our environmental research is conducted under SeedLabs, which was founded to advance novel bacterial interventions to enhance biodiversity and restore ecosystems impacted by human activity. Media Contact[email protected]
05/16 17:28 EST - globenewswire.com
Precision Drilling Corporation Announces Voting Results from the 2024 Annual and Special Meeting of Shareholders
CALGARY, Alberta, May 16, 2024 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision or the Company) is pleased to announce the results of the election of board members at its 2024 Annual and Special Meeting of Shareholders held on May 16, 2024 (the Annual Meeting). Shareholders approved the election of all eight (seven of whom are independent) of the nominee directors presented in the Company's Management Information Circular (the Circular), dated April 3, 2024.
Precision Drilling Corporation Announces Voting Results from the 2024 Annual and Special Meeting of Shareholders
CALGARY, Alberta, May 16, 2024 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision or the Company) is pleased to announce the results of the election of board members at its 2024 Annual and Special Meeting of Shareholders held on May 16, 2024 (the Annual Meeting). Shareholders approved the election of all eight (seven of whom are independent) of the nominee directors presented in the Company's Management Information Circular (the Circular), dated April 3, 2024.